The LCDs are withdrawn - but the uncertainty isn’t over.

CMS’ decision to withdraw the future-effective skin substitute LCDs removes immediate coverage restrictions, but it does not resolve the underlying challenges facing wound care. Without clear guidance, coverage decisions may shift to individual claim reviews and Medicare Advantage policies, while the $127/cm² physician fee schedule continues to pressure clinical decision-making.

Sustainable progress will require alignment across reimbursement, coverage, and evidence - with patient access at the center.